

**SENATE BILL No. 199**

By Senators Pilcher-Cook, Abrams, Apple, Arpke, Bruce, Donovan, Fitzgerald, Holmes, Kerschen, LaTurner, Love, Lynn, Masterson, Melcher, O'Donnell, Olson, Ostmeier, Petersen, Powell, Pyle, Smith and Wagle

2-13

1 AN ACT concerning the university of Kansas medical center; establishing  
2 the midwest stem cell therapy center.

3  
4 *Be it enacted by the Legislature of the State of Kansas:*

5 Section 1. (a) The university of Kansas medical center shall establish  
6 the midwest stem cell therapy center. The center shall:

7 (1) Focus on activities that advance adult, cord blood and related stem  
8 cell and non-embryonic stem cell research and therapies for patient  
9 treatment;

10 (2) serve as a core facility to produce clinical grade stem cells from  
11 adult tissues, cord blood and related materials for use in clinical trials and  
12 therapies;

13 (3) facilitate the delivery of adult, cord blood and related stem cell  
14 therapies to Kansas City and midwest region hospitals where appropriate;

15 (4) foster a regional network of physicians trained in adult, cord  
16 blood and related stem *cell* therapy applications;

17 (5) create and maintain a database resource for physicians and  
18 patients that provides a comprehensive global list of available stem cell  
19 clinical trials and therapies;

20 (6) initiate clinical trials with adult, cord blood and related stem cells;

21 (7) create education modules to train and educate physicians and  
22 research scientists about peer-reviewed adult, cord blood and related stem  
23 cell therapy applications for patients;

24 (8) distribute information to Kansas physicians about methods for  
25 successful treatments with adult, cord blood and related stem cells through  
26 basic and clinical research; and

27 (9) inform the public on available adult, cord blood and related stem  
28 cell therapeutic options.

29 Sec. 2. (a) The executive vice chancellor of the university of Kansas  
30 medical center shall appoint the director of the midwest stem cell therapy  
31 center.

32 (b) The director shall report to the executive vice chancellor of the  
33 university of Kansas medical center.

34 (c) The director of the midwest stem cell therapy center shall have

1 experience in adult or cord blood stem cell research and experience in  
2 clinical applications of adult or cord blood stem cell therapies.

3 (d) The director of the midwest stem cell therapy center shall be  
4 responsible for administration of the midwest stem cell therapy center,  
5 including the overall direction of personnel, equipment and facilities;

6 (e) The director of the midwest stem cell therapy center shall be  
7 responsible for ~~oversight~~ **coordination** of patient treatment and research  
8 with adult, cord blood and related stem cells and non-embryonic stem  
9 cells;

10 (f) The director of the midwest stem cell therapy center is hereby  
11 authorized to solicit and receive grants, gifts, contributions or bequests  
12 made for the purpose of furthering the goals and missions of the midwest  
13 stem cell therapy center. The director of the midwest stem cell therapy  
14 center shall remit all moneys so received to the state treasurer in  
15 accordance with the provisions of K.S.A. 75-4215, and amendments  
16 thereto. Upon receipt of each such remittance, the state treasurer shall  
17 deposit the entire amount in the state treasury to the credit of the midwest  
18 stem cell therapy center fund.

19 (g) Fees received for core charges for cell processing and  
20 manufacturing, clinical trial fees and similar service charges shall be paid  
21 to the university of Kansas medical center research institute, inc. or  
22 university of Kansas endowment, as determined by the director.

23 (h) The university of Kansas endowment association may accept gifts  
24 directly designated for the benefit of the midwest stem cell therapy center  
25 consistent with its corporate purpose as a nonprofit charitable corporation  
26 whose mission seeks the advancement of the university of Kansas.

27 Sec. 3. (a) There is hereby established in the state treasury the  
28 midwest stem cell therapy center fund. Expenditures from the fund may be  
29 made for the purposes of furthering the goals and missions of the midwest  
30 stem cell therapy center and for such other purposes as may be specified  
31 with regard to any grant, gift, contribution or bequest. All such  
32 expenditures shall be authorized by the director of the midwest stem cell  
33 therapy center and made upon warrants of the director of accounts and  
34 reports issued pursuant to vouchers approved by the director of midwest  
35 stem cell therapy center.

36 (b) On or before the 10<sup>th</sup> of each month, the director of accounts and  
37 reports shall transfer from the state general fund to the midwest stem cell  
38 therapy center fund interest earnings based on:

39 (1) The average daily balance of moneys in the midwest stem cell  
40 therapy center fund for the preceding month; and

41 (2) the net earnings rate for the pooled money investment portfolio  
42 for the preceding month.

43 Sec. 4. (a) There is hereby established the advisory board to the

1 midwest stem cell therapy center which shall be composed of 13 members  
2 and one ex officio member as follows:

3 (1) One person representing the patient community appointed by the  
4 governor and such original member shall serve two years;

5 (2) one person representing the physician community appointed by  
6 the governor and such original member shall serve three years;

7 (3) one person representing the university of Kansas appointed by the  
8 state board of regents and such original member shall serve one year;

9 (4) one person representing Kansas state university appointed by the  
10 state board of regents and such original member shall serve one year;

11 (5) one person representing the university of Kansas medical center  
12 appointed by the executive vice chancellor and such original member shall  
13 serve three years;

14 (6) one person representing the institute for advancing medical  
15 innovation appointed by the director of the institute for advancing medical  
16 innovation and such original member shall serve one year;

17 (7) one person representing the university of Kansas cancer center  
18 appointed by the director of the university of Kansas cancer center and  
19 such original member shall serve two years;

20 (8) one person representing the university of Kansas hospital  
21 authority appointed by the board of directors of the university of Kansas  
22 hospital authority and such original member shall serve for one year;

23 (9) one member of the house of representatives appointed by the  
24 speaker of the house and such original member shall serve for two years;

25 (10) one member of the senate appointed by the president of the  
26 senate and such original member shall serve for three years;

27 (11) one person with a nationally respected reputation representing  
28 the physician community appointed by the speaker of the house and such  
29 original member shall serve three years;

30 (12) one person with a nationally respected reputation representing  
31 the scientific research community appointed by the president of the senate  
32 and such original member shall serve one year;

33 (13) one member of the executive branch of the state agencies  
34 appointed by the governor and such original member shall serve for two  
35 years; and

36 (14) the director of the midwest stem cell therapy center as an ex  
37 officio member of the board.

38 (b) The appointments to the advisory board shall be for terms of three  
39 years, except as provided for the original members in subsection (a). No  
40 member shall be appointed to the advisory board for more than three  
41 consecutive terms. Upon the expiration of the term of office of any  
42 member of the advisory board on or after the effective date of this act, and  
43 in any case of a vacancy existing on or after the effective date of this act, a

1 successor shall be appointed by the appropriate entity pursuant to this  
2 section.

3 (c) The advisory board shall serve in an advisory role to the director  
4 of the midwest stem cell therapy center.

5 (d) Duties of members may include fundraising, public speaking and  
6 other public relation activities to advance public awareness of successful  
7 adult, cord blood and related stem cell therapeutic options.

8 (e) The governor shall appoint the chairperson of the advisory board  
9 and the chairperson may serve consecutive terms. The advisory board shall  
10 meet at least four times each year and at such other times as it deems  
11 appropriate, or upon call of the chairperson.

12 (f) All members of the advisory board shall serve without  
13 compensation.

14 Sec. 5. All funds and facilities of the midwest stem cell therapy center  
15 shall be dedicated to treatments and research with adult, cord blood and  
16 related stem cells and non-embryonic stem cells. No funds or facilities of  
17 the midwest stem cell therapy center shall involve embryonic stem cells or  
18 fetal tissue cells.

19 Sec. 6. As used in sections 1 through 5, and amendments thereto:

20 (a) "Adult, cord blood and related stem cells" are stem cells derived  
21 from postnatal tissue cells, umbilical cord blood and cord tissue including  
22 Wharton's jelly, amniotic fluid and placental tissue.

23 (b) "Embryonic stem cells" are stem cells derived from early stage  
24 human embryos, up to and including the blastocyst stage.

25 (c) "Facilities" include all equipment used by the midwest stem cell  
26 therapy center.

27 (d) "Fetal tissue cells" are cells harvested from aborted fetal tissue.

28 (e) "Non-embryonic stem cells" are stem cells such as iPS cells  
29 (induced pluripotent stem cells) generated from adult somatic cells or  
30 other non-embryonic tissue cells without any embryonic component.

31 Sec. 7. This act shall take effect and be in force from and after its  
32 publication in the statute book.